BPC-157 vs Ghrelinomimetic

A side-by-side comparison from PeptideSciences101, the open peptide reference.

Overview

BPC-157 is primarily a bone & joint peptide, while Ghrelinomimetic is used for healing & recovery.

This page compares BPC-157 and Ghrelinomimetic across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

BPC-157Ghrelinomimetic
CategoryBone & JointHealing & Recovery
Regulatory status (US)Compounding (Rx) — Apr 2026Research use only
Typical dosage250-500 mcg100-200 mcg
Frequencydailydaily
Reported benefitsAccelerated bone healing, cartilage repair, joint supportIncreased appetite, gut healing, muscle preservation
Reported side effectsMinimal side effectsIncreased hunger, water retention

Key differences

Primary use. BPC-157 is categorised under Bone & Joint, while Ghrelinomimetic falls under Healing & Recovery. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.

Regulatory status. BPC-157: not FDA-approved; compounding permitted with a prescription as of April 2026. Ghrelinomimetic: not FDA-approved; treated as a research compound.

Dosing. BPC-157 is typically dosed at 250-500 mcg (daily). Ghrelinomimetic is typically dosed at 100-200 mcg (daily).

Can you stack them?

Some protocols combine peptides, but stacking BPC-157 and Ghrelinomimetic has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between BPC-157 and Ghrelinomimetic?
BPC-157 is primarily a bone & joint peptide, while Ghrelinomimetic is used for healing & recovery. BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Ghrelinomimetic is not FDA-approved; generally classified as a research compound.
What is BPC-157 used for?
Bone and cartilage healing.
What is Ghrelinomimetic used for?
Appetite and healing support.
Can you take BPC-157 and Ghrelinomimetic together?
Some users combine peptides within a single protocol, but stacking BPC-157 and Ghrelinomimetic has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
Is BPC-157 or Ghrelinomimetic FDA-approved?
BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026). Ghrelinomimetic is not FDA-approved; generally classified as a research compound.

Read the full articles

  • BPC-157 — full monograph: mechanism, research, dosing & references
  • Ghrelinomimetic — full monograph: mechanism, research, dosing & references

More Bone & Joint comparisons

← All peptide comparisons